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Abstract
Controlling tumour margins in head and neck surgery is of the utmost importance in preventing loco-regional
spread and distant metastasis, which will ultimately lead to a significant reduction in morbidity and mortality. We
comment on the surgical margins in photodynamic therapy and photochemical internalization.
Introduction
Several studies assessing diseased tissues in the head and
neck region have identified two clinic-pathological para-
meters, the surgical margin and nodal involvement,
which are of utmost importance in assessing tumour-
related progression, recurrence, morbidity and mortality
[1].
The surgical margin concept has been around for
sometime now. It represents the visible margin of
macroscopically tumour-free area during surgery or his-
topathologically proven tumour-free area during proces-
sing of the specimen. The status of this margin has been
identified to play a vital role in assessing disease status
in the head and neck. For example, the presence of
non-cohesive invasive front, dysplasia at margin, lym-
pho-vascular invasion, nerve invasion and bone/cartilage
may suggest aggressive cancerous growth which is more
likely to resist adjuvant therapy and have high recur-
rence rate [1].
The traditional treatment for any cancer may include
3 modalities: surgery, radiotherapy and chemotherapy.
Development in scientific methodology and clinical
research has lead to identification of other modalities
that were found superior to the traditional ones for spe-
cific diseases of certain stage and grade (i.e. hormonal
therapy for early prostate cancer), also the identification
of other non-traditional adjuvant therapy that could
improve the efficacy of other treatments or sometimes
act independently (i.e. immunotherapy).
When managing head and neck disease, surgery con-
tinue to be the primary intervention with chemo-
radiation as adjuvant therapy; but have been applied as
neo-adjuvant in certain cases. Keeping an open mind in
cancer management is a must as no “magic bullet” has
been identified to date and most interventions are
equally effective, leading mostly to poor survival rates in
most cancers.
Over the last 2 decades, photodynamic therapy (PDT)
was introduced as a minimally-invasive surgical modality
in cancer management and several studies have proved
its usefulness in oncological care [2,3].
Photodynamic therapy
Using different photo-sensitizers, PDT successfully tar-
geted pathologies in the head and neck, skin, brain,
lung, pancreas, intra-peritoneal cavity, breast and pros-
tate. The resultant photochemical reaction (between a
photosensitizer, oxygen in the suspect tissue and the
light delivered) lasts for few hours and leads to selective
injury to the target tissue. All the clinical studies pub-
lished on this technology showed that PDT is compar-
able to all the three conventional modalities (i.e.
surgery, radiotherapy and chemotherapy) when it comes
to disease mortality in the head and neck but identified
PDT to be superior as it causes much less morbidity
[2,3].
The growing body of evidence regarding PDT’s effi-
cacy suggests that it will have a leading role in mini-
mally-invasive surgical oncology. Long-term studies
showed that the outcome improves when PDT is offered
on a repeatable basis rather than one time only. A
recent study on T1/T2 oral cancer showed that 3
rounds of PDT are as successful as surgery in terms of
mortality with minimal morbidity. The repeatability is
required as residual or recurrent tumour islands have
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been identified in previously treated PDT-margins (sur-
gical margins), according to the study [4]. It is worth to
highlight the fact that most of the cohort included
patients with thick T2 disease with moderately to poorly
differentiated squamous cell carcinomas. Surgical biop-
sies identified several parameters indicating aggressive
tumour growth.
It is hoped that with the development of third genera-
tion photo-sensitizers or advancement in photodynamic
applications (i.e. photochemical internalization), a real
solution to surgical margins problem in PDT may be
found.
Photochemical internalization
Photochemical internalization (PCI) is a novel technol-
ogy facilitates the delivery of macromolecules into cyto-
plasm. It can best be described as sub-lethal PDT
facilitating the effect of chemotherapy. The initial
mechanism and practical application was described by
Berg et al. in 1999 [5]. In 2001, the same group docu-
mented the in vivo approach to site-specific cancer ther-
apy via photochemical internalization. The outcome of
the study revealed synergetic effect of combing photo-
activation of photosensitizer and gelonin and the resul-
tant PCI reaction [6]. These findings highlighted the
potential clinical usefulness of PCI in cancer therapy,
gene therapy and vaccination. In 2005, bleomycin was
introduced as the chemotherapeutic agent in PCI [7].
Discussion
A recent in vitro study by Norum et al. [8] had shown
that photodynamic therapy (PDT) is less efficient in the
tumor periphery than in the tumor center, when com-
pared to photochemical internalization (PCI). In their
study, they suggested that PCI may release endocytosed
bleomycin into the
cytosol by photochemical rupture of the endocytic
vesicles and that PCI caused larger necrotic areas and
the regrowth in the peripheral zone was almost com-
pletely inhibited after PCI. This study suggested that
the PCI effect may result in tumour clearance in the
peripheries (surgical margin) of the treated cancerous
lesions.
The first PCI trial in humans, using amphinex as the
photosensitiser and bleomycin as the chemotherapeutic
agent are taking place at University College London
Hospital. The trial clinical results, when published, will
help shed light on the real effect of PCI on the surgical
margins or peripheries of human pathologies.
Conclusion
Controlling tumour margins is of the utmost importance
in preventing loco-regional spread and distant
metastasis, which will ultimately lead to a significant
reduction in morbidity and mortality.
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